News

Schrödinger announced it will discontinue clinical development of the CDC7 inhibitor SGR-2921 for acute myeloid leukemia (AML) and myelodysplastic syndromes following two patient deaths in an ...
Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.
A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...
There’s a new twist in the fight against bladder cancer — and it’s delivering game-changing results. In a recent clinical ...
ABC News' Dr. Tara Narula breaks down a potential non-surgical breakthrough as the FDA fast-tracks review of a first-of-its-kind bladder cancer treatment.
Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...
The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.
In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...
In this Phase III trial, the Padcev-Keytruda combination used as both neoadjuvant and adjuvant therapy significantly improved event-free and overall survival, as well as pathologic complete response, ...
On Tuesday, Merck & Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for ...
US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 ...
The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.